Table 5 Relation between CDKN2B-AS1 (rs1333049) gene polymorphism and laboratory data and prognosis in moderate COVID-19 cases (n = 90)

WBCs

4.00–11/(mcL)

Median

8.20

11.0

11.20

 H = 2.058

0.357

Platelet

150–400/(mcL)

Median

318.0

215.50

207.0

 H = 16.271^*

< 0.001^*

HB (g/dl)

Male: 14–18 g/dL

Mean ± SD.

Female: 12–16 g/dL

12.14 ± 2.24

11.88 ± 2.17

10.48 ± 1.61

 F = 4.64^*1

0.012^*

SGOT (U/L)

8–45 (U/L)

Median

29.0

38.0

45.0

 H = 4.254

0.119

SGPT (U/L)

7–56 (U/L)

Median

30.0

34.0

29.50

 H = 0.983

0.612

BUN (mg/dL)

6–24 mg/dL

Median

26.0

32.50

22.0

 H = 1.238

0.539

Creatinine (mg/dL)

Male: 0.6-1.2 mg/dL

Median

Female: 0.5 to 1.1 mg/dL

0.88

1.05

0.75

 H = 5.451

0.066

Na⁺(mEq/L)

135–145 (mEq/L)

Mean ± SD.

139.22 ± 5.37

138.29 ± 5.96

136.83 ± 5.62

 F = 0.950

0.391

 K⁺(mEq/L)

3.5–5.3 (mEq/L

Mean ± SD.

4.44 ± 0.68

4.14 ± 0.78

4.26 ± 0.54

 F = 1.214

0.302

TG (mg/dL)

Male: 40–160 mg/dL

Median

Female: 35–135 mg/dL

108.0

117.0

150.0

 H = 4.143

0.126

Cholesterol (mg/dL)

125–200 mg/dL

Median

111.0

102.50

114.50

 H = 1.248

0.536

HDL (mg/dL)

Male: 35–55 mg/dL

Median

Female: 45–65 mg/dL

33.50

34.0

34.0

 H = 1.012

0.603

LDL (mg/dL)

< 130 mg/dL

Median

54.60

48.10

52.50

 H = 2.403

0.301

PC%

Mean ± SD.

79.03 ± 15.05

74.11 ± 17.80

87.92 ± 12.10

 F = 6.007

< 0.001^*

INR

0.9–1.1

Median

1.16

1.20

1.05

 H = 14.456^*

< 0.001^*

CRP (mg/L)

< 3 mg/L

Median

17.0

55.0

24.0

 H = 6.043^*

0.048^*

Ferritin (µg/L)

Male: 24–336 (µg/L)

Median

Female: 11–307 (µg/L)

250.0

523.0

305.0

 H = 7.892*

0.019^*

D-dimer (µg/mL)

0-0.50 (µg/mL)

Median

0.63

0.80

0.90

 H = 1.1.474

0.479

Prognosis

Improved

12 (66.7%)

26 (54.2%)

16 (66.7%)

χ²=1.458

0.482

Death

6 (33.3%)

22 (45.8%)

8 (33.3%)